Many botanicals advocated or researched for the treatment of cancer are thought to act via an immune mechanism. Their interaction with antibody-mediated cytotoxicity has not been previously explored. Tumor-specific antibodies now play major roles in the standard treatment of several human cancers, including trastuzumab (Herceptin) for breast cancer, rituximab (Rituxan) and alemtuzumab (Campath) for lymphorina and Cetuximab (Erbitux) for colon cancer. Natural or induced anti-tumor antibodies have also been correlated with favorable clinical outcomes in a number of human cancers. Through antibody, both complement mediated cytotoxicity (CMC) and cell-mediated cytotoxicity (ADCC) have played key roles. Besides Fc receptors, complement receptor 3 (CR3) is now found to be essential for ADCC in both in vitro and in vivo models. Beta-glucan is a major ingredient in many botanicals and when orally administered is transported by gut macrophages to the marrow where the processed carbohydrate is released to allow activation of the CR3 on leukocytes. In the presence of anti-tumor antibodies, this increased avidity of CR3 translates into highly efficient tumor kill. Therapies designed rationally on the basis of this mechanistic knowledge have been highly effective in animal models and early clinical trials. In this grant application, we hypothesize that botanicals can impact on these anti-tumor mechanisms by enhancing effector functions of leukocytes in ADCC through modulation of FcR, CR3 as well as other critical adhesion molecules. We propose to study oral administration of botanicals in combination with intravenous intravenous injection of anti-tumor antibodies in human xenograft models. Botanicals will also be tested for binding to CR3, and in vivo activation of CR3, FcR and integrins on leukocytes, as well as in vivo activation of neutrophil and .macrophage mediated tumor cytotoxicity. CR3-dependent tumor cytotoxicity for both IgM (innate) or IgG (induced) anti-tumor antibodies will be examined. For those botanicals with significant anti-tumor effects, the importance of CR3 will be confirmed using knockout mice. Although initial experiments will be carried out on five botanicals, we expect to screen a total of 46. Our findings will: a) suggest candidate botanicals for clinical trial in combination with antibodies or vaccines; b) form the basis of a general screening tool and quality control; c) provide leads for further research in the other projects that focus on vaccines, dendritic cells, T-cells and NK cells in different disease models.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Specialized Center (P50)
Project #
5P50AT002779-04
Application #
7641076
Study Section
Special Emphasis Panel (ZAT1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
4
Fiscal Year
2008
Total Cost
$145,273
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Wesa, Kathleen M; Cunningham-Rundles, Susanna; Klimek, Virginia M et al. (2015) Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother 64:237-47
Fonseca, Fabiana N; Papanicolaou, Genovefa; Lin, Hong et al. (2014) Echinacea purpurea (L.) Moench modulates human T-cell cytokine response. Int Immunopharmacol 19:94-102
Yue, Grace G L; Cheng, Sau-Wan; Yu, Hua et al. (2012) The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells. J Med Food 15:242-52
Xiao, Wei-Lie; Motley, Timothy J; Unachukwu, Uchenna J et al. (2011) Chemical and genetic assessment of variability in commercial Radix Astragali (Astragalus spp.) by ion trap LC-MS and nuclear ribosomal DNA barcoding sequence analyses. J Agric Food Chem 59:1548-56
Yuan, Jianda; Ginsberg, Brian; Page, David et al. (2011) CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60:1137-46
Hong, Feng; Xiao, Weilie; Ragupathi, Govind et al. (2011) The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines. Planta Med 77:817-24
Yue, Grace G L; Chan, Ben C L; Hon, Po-Ming et al. (2010) Immunostimulatory activities of polysaccharide extract isolated from Curcuma longa. Int J Biol Macromol 47:342-7
Fusco, Dahlene; Liu, Xinyan; Savage, Caroline et al. (2010) Echinacea purpurea aerial extract alters course of influenza infection in mice. Vaccine 28:3956-62
Lin, Hong; de Stanchina, Elisa; Zhou, Xi Kathy et al. (2010) Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer Immunol Immunother 59:885-97
Yue, Grace G L; Chan, Ben C L; Hon, Po-Ming et al. (2010) Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa. Food Chem Toxicol 48:2011-20

Showing the most recent 10 out of 28 publications